Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma
-
摘要: 目的探讨含苯达莫司汀的移植预处理方案[BeEAM(苯达莫司汀+依托泊苷+阿糖胞苷+马法兰)和BeEAC(苯达莫司汀+依托泊苷+阿糖胞苷+环磷酰胺)]在淋巴瘤自体造血干细胞移植(ASCT)中的疗效及安全性。方法回顾性分析2020年10月—2022年5月在潍坊市人民医院血液科接受ASCT的13例非霍奇金淋巴瘤患者，分析造血重建时间，并评估疗效及不良反应。结果ASCT前完全缓解10例，部分缓解3例。13例患者移植后均造血重建，中性粒细胞中位植活时间10(9~16)d，血小板中位植活时间14(9~22)d。移植后中位随访11(3~19)个月，患者移植后3个月完全缓解率为84.6%(11/13)，主要的2级以上不良反应为发热性中性粒细胞减少、恶心、呕吐、腹泻、口腔黏膜炎，无移植相关死亡。结论BeEAM和BeEAC预处理后ASCT均是治疗恶性淋巴瘤安全、有效的方法，其远期疗效尚待长期随访观察。Abstract: ObjectiveTo explore the safety and efficacy of bendamustine in the conditioning regimen for autologous hematopoietic stem cell transplantation(ASCT) in patients with lymphoma.MethodsFrom October 2020 to May 2022, 13 patients with malignant lymphoma who underwent ASCT in our hospital were retrospectively analyzed. The time of hematopoietic reconstitution was analyzed, and the curative effect and adverse events were evaluated.ResultsTen patients achieved complete remission and 3 patients achieved partial remission hefore ASCT. All 13 patients achieved hematopoietic reconstitution after ASCT. The median engraftment time of neutrophils was 10(9-16) days, and the median engraftment time of platelets was 14(9-22) days. The median follow-up was 11(3-19) months after ASCT, and the complete remission rate was 84.6%(11/13) at 3 months after transplantation. The main adverse events above grade 2 were febrile neutropenia, nausea, vomiting, diarrhea, and oral mucositis. There were no transplant-related death.ConclusionASCT after BeEAM and BeEAC conditioning is a safe and effective method for the treatment of malignant lymphoma. The long-term efficacy of the conditioning regimen needs to be evaluated by long-term follow-up.
-
Key words:
- autologous stem cell transplantation /
- lymphoma /
- bendamustine /
- conditioning regimen
-
-
表 1 13例患者的不良反应
例(%) 不良反应 1~2级 3~4级 发热性中性粒细胞减少 7(53.8) 2(15.4) 贫血 12(92.3) 1(7.7) 胃肠道毒性 腹泻 6(46.2) 0 恶心、呕吐 7(53.8) 0 口腔黏膜炎 4(30.8) 1(7.7) 急性肾损伤 2(15.4) 0 
下载: 导出CSV
-
[1] Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma[J]. Lancet, 2017, 390(10091): 298-310. doi: 10.1016/S0140-6736(16)32407-2
[2] Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress[J]. CA Cancer J Clin, 2018, 68(2): 116-132. doi: 10.3322/caac.21438
[3] Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed /refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning[J]. Leuk Lymphoma, 2016, 57(11): 2499-2509. doi: 10.1080/10428194.2016.1185785
[4] Shi Y, Liu P, Zhou S, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity[J]. Asia Pac J Clin Oncol, 2017, 13(5): e423-429. doi: 10.1111/ajco.12610
[5] Ogura M, Uehida T, Taniwaki M, et al. Phase I and pharmacokinetie study of bendamustine hydrochloride in relapsed or refractory indolent B cell non-Hodgkin lymphoma and mantle cell lymphoma[J]. Cancer Sci, 2010, 101(9): 2054-2058. doi: 10.1111/j.1349-7006.2010.01633.x
[6] Leoni LM, Bailey B, Reifert J, et al. Bendamustine(Treanda)displays a distinct pattern of cytotoxicity and unique mechanistic fealures compared with other alkylating agents[J]. Clin Cancer Res, 2008, 14(1): 309-317. doi: 10.1158/1078-0432.CCR-07-1061
[7] Visani G, Malerba L, Stefani PM, et al. BeEAM(bendamustine, etoposide, cytarabine, melphalan)before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients[J]. Blood, 2011, 118(12): 3419-3425. doi: 10.1182/blood-2011-04-351924
[8] Visani G, Stefani PM, Capria S, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma[J]. Blood, 2014, 124(19): 3029-3031. doi: 10.1182/blood-2014-08-596668
[9] Noesslinger T, Moestl M, Tinchon C, et al. Autologous stem cell transplantation with benda-EAM(bendamustine, etoposide, cytarabine, melphalan)in aggressive non Hodgkin and Hodgkin's lymphoma[J]. Blood, 2014, 124(21): 3982-3982. doi: 10.1182/blood.V124.21.3982.3982
[10] Martino M, Messina G, Moscato T, et al. Bendamustine Plus Melphalan As Conditioning Regimen for Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Single Centre Experience[J]. Blood, 2014, 124(21): 2516-2516. doi: 10.1182/blood.V124.21.2516.2516
[11] Garciaz S, Coso D, Schiano de Collela JM, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity[J]. Bone Marrow Transplant, 2016, 51(2): 319-321. https://www.nature.com/articles/bmt2015257
[12] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
[13] Xiong YY, Fan Q, Huang F, et al. Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: a pilot prospective, open-label, randomized trial[J]. Biol Blood Marrow Transplant, 2014, 20(2): 236-342. doi: 10.1016/j.bbmt.2013.11.002
[14] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068. doi: 10.1200/JCO.2013.54.8800
[15] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组, 中国临床肿瘤学会抗淋巴瘤联盟. 造血干细胞移植治疗淋巴瘤中国专家共识(2018版)[J]. 中华肿瘤杂志, 2018(40): 927-993.
[16] Chantepie SP, Garciaz S, Tchernonog E, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation(ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association(LYSA)centers[J]. Am J Hematol, 2018, 93(6): 729-735. https://onlinelibrary.wiley.com/doi/10.1002/ajh.25077
[17] Kim DY, Chung JS, Jo JC, et al. Phase Ⅱ study of safety and efficacy of BEB(bendamustine, etoposide, and busulfan)conditioning regimen for autologous stem cell transplantation in non-Hodgkinlymphoma[J]. Ann Hematol, 2020, 99(4): 819-828. doi: 10.1007/s00277-020-03942-6
[18] Redondo AM, Valcarcel D, Gonzalez-Rodriguez AP, et al. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group[J]. Br J Haematol, 2019, 184(5): 797-807.
-